PMID- 27425586
OWN - NLM
STAT- MEDLINE
DCOM- 20171219
LR  - 20181202
IS  - 1468-1331 (Electronic)
IS  - 1351-5101 (Print)
IS  - 1351-5101 (Linking)
VI  - 23
IP  - 10
DP  - 2016 Oct
TI  - Impulse control disorder related behaviours during long-term rotigotine 
      treatment: a post hoc analysis.
PG  - 1556-65
LID - 10.1111/ene.13078 [doi]
AB  - BACKGROUND AND PURPOSE: Dopamine agonists in Parkinson's disease (PD) are 
      associated with impulse control disorders (ICDs) and other compulsive behaviours 
      (together called ICD behaviours). The frequency of ICD behaviours reported as 
      adverse events (AEs) in long-term studies of rotigotine transdermal patch in PD 
      was evaluated. METHODS: This was a post hoc analysis of six open-label extension 
      studies up to 6 years in duration. Analyses included patients treated with 
      rotigotine for at least 6 months and administered the modified Minnesota Impulse 
      Disorders Interview. ICD behaviours reported as AEs were identified and 
      categorized. RESULTS: For 786 patients, the mean (+/-SD) exposure to rotigotine was 
      49.4 +/- 17.6 months. 71 (9.0%) patients reported 106 ICD AEs cumulatively. 
      Occurrence was similar across categories: 2.5% patients reported 'compulsive 
      sexual behaviour', 2.3% 'buying disorder', 2.0% 'compulsive gambling', 1.7% 
      'compulsive eating' and 1.7% 'punding behaviour'. Examining at 6-month intervals, 
      the incidence was relatively low during the first 30 months; it was higher over 
      the next 30 months, peaking in the 54-60-month period. No ICD AEs were serious, 
      and 97% were mild or moderate in intensity. Study discontinuation occurred in 
      seven (9.9%) patients with ICD AEs; these then resolved in five patients. Dose 
      reduction occurred for 23 AEs, with the majority (73.9%) resolving. CONCLUSIONS: 
      In this analysis of >750 patients with PD treated with rotigotine, the frequency 
      of ICD behaviour AEs was 9.0%, with a specific incidence timeline observed. 
      Active surveillance as duration of treatment increases may help early 
      identification and management; once ICD behaviours are present rotigotine dose 
      reduction may be considered.
CI  - (c) 2016 The Authors. European Journal of Neurology published by John Wiley & Sons 
      Ltd on behalf of European Academy of Neurology.
FAU - Antonini, A
AU  - Antonini A
AD  - Parkinson Unit, IRCCS Hospital San Camillo, Venice, Italy. angelo3000@yahoo.com.
FAU - Chaudhuri, K R
AU  - Chaudhuri KR
AD  - National Parkinson Foundation International Centre of Excellence, King's College 
      Hospital, King's College, London, UK.
FAU - Boroojerdi, B
AU  - Boroojerdi B
AD  - UCB Pharma, Monheim am Rhein, Germany.
FAU - Asgharnejad, M
AU  - Asgharnejad M
AD  - UCB Pharma, Raleigh, NC, USA.
FAU - Bauer, L
AU  - Bauer L
AD  - UCB Pharma, Monheim am Rhein, Germany.
FAU - Grieger, F
AU  - Grieger F
AD  - UCB Pharma, Monheim am Rhein, Germany.
FAU - Weintraub, D
AU  - Weintraub D
AD  - Departments of Psychiatry and Neurology, University of Pennsylvania School of 
      Medicine, Philadelphia, PA, USA.
AD  - Parkinson's Disease and Mental Illness Research, Education and Clinical Centers 
      (PADRECC and MIRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, 
      PA, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160718
PL  - England
TA  - Eur J Neurol
JT  - European journal of neurology
JID - 9506311
RN  - 0 (Dopamine Agonists)
RN  - 0 (Tetrahydronaphthalenes)
RN  - 0 (Thiophenes)
RN  - 87T4T8BO2E (rotigotine)
SB  - IM
MH  - Aged
MH  - Disruptive, Impulse Control, and Conduct Disorders/*chemically induced
MH  - Dopamine Agonists/*adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Parkinson Disease/*drug therapy
MH  - Tetrahydronaphthalenes/*adverse effects
MH  - Thiophenes/*adverse effects
PMC - PMC5096013
OTO - NOTNLM
OT  - Parkinson's disease
OT  - clinical trial
OT  - dopamine agonists
OT  - impulse control disorders
OT  - long-term treatment
OT  - rotigotine transdermal patch
EDAT- 2016/07/19 06:00
MHDA- 2017/12/20 06:00
PMCR- 2016/11/04
CRDT- 2016/07/19 06:00
PHST- 2016/05/18 00:00 [received]
PHST- 2016/06/09 00:00 [accepted]
PHST- 2016/07/19 06:00 [entrez]
PHST- 2016/07/19 06:00 [pubmed]
PHST- 2017/12/20 06:00 [medline]
PHST- 2016/11/04 00:00 [pmc-release]
AID - ENE13078 [pii]
AID - 10.1111/ene.13078 [doi]
PST - ppublish
SO  - Eur J Neurol. 2016 Oct;23(10):1556-65. doi: 10.1111/ene.13078. Epub 2016 Jul 18.